Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12510639 | 0.91 | KDM4E (0.42) | CA12CA2CA3CA4CA6 | |
| SCHEMBL6166961 | 0.90 | KDM4E (0.45) | CA12CA2CA3CA4CA6 | |
| SCHEMBL24362159 | 0.88 | KDM4E (0.41) | CA12CA2CA3CA4CA6 | |
| SCHEMBL14271449 | 0.87 | KDM4E (0.43) | CA12CA2CA3CA4CA6 | |
| SCHEMBL19212955 | 0.87 | KDM4E (0.43) | CA12CA2CA3CA4CA6 | |
| SCHEMBL8347626 | 0.86 | CHRM2 (0.40) | CA12CA2CA3CA4CA6 | |
| SCHEMBL14996390 | 0.86 | KDM4E (0.39) | CA12CA2CA3CA4CA6 | |
| SCHEMBL2201485 | 0.86 | KDM4E (0.39) | CA12CA2CA3CA4CA6 | |
| SCHEMBL11714331 | 0.86 | MAPT (0.41) | CA12CA2CA3CA4CA6 | |
| SCHEMBL232247 | 0.84 | MEN1 (0.39) | KDM4EALDH1A1SIGMAR1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771715-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11766449-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11679120-B2 | Circular RNA compositions and methods | ORNA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| EP-3960726-A9 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-3960726-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |
| EP-3922267-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2021-12-15 | — | — | EP | disclosed |
| EP-3597644-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2021-09-29 | — | — | EP | disclosed |
| US-11059807-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| CN-108779419-B | Cleaning agent composition for electronic material, cleaning agent stock solution, and method for cleaning electronic material | 荒川化学工业株式会社 | 2021-04-20 | — | — | CN | disclosed |
| EP-3050576-B1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S (DK) | 2021-03-31 | — | — | EP | disclosed |
| EP-3050576-A1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | Ascendis Pharma Growth Disorders Division A/S (DK) | 2016-08-03 | — | — | EP | disclosed |
| EP-2279007-B1 | PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS | ASCENDIS PHARMA GROWTH DISORDERS DIVISION AS (DK) | 2016-05-18 | — | — | EP | disclosed |
| US-20160113874-A1 | NOVEL CATATONIC LIPIDS WITH VARIOUS HEAD GROUPS FOR OLIGONUCLEOTIDE DELIVERY | BANK OF AMERICA, N.A. | 2016-04-28 | — | — | US | disclosed |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20120253032-A1 | NOVEL CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR OLIGONUCLEOTIDE DELIVERY | MERCK SHARP & DOHME CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | METASTATIX, INC. | 2008-10-23 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-07-12 | — | — | US | disclosed |
| WO-1994007869-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113874-A1 | NOVEL CATATONIC LIPIDS WITH VARIOUS HEAD GROUPS FOR OLIGONUCLEOTIDE DELIVERY | NPC1L1, NPC1, ABCB4 | CA12 1878/4885CA2 1585/4885CA3 1261/4885 |
| US-11771715-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA2 4784/4885CA3 4577/4885 |
| US-20080261978-A1 | treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea | MKI67, CCNI, CDKN1A | CA12 4601/4885CA2 4241/4885CA3 4753/4885 |
| US-11059807-B2 | Amine cationic lipids and uses thereof | SGMS2, SLC43A1, SGMS1 | CA12 4718/4885CA2 4682/4885CA3 4794/4885 |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | CA12 1257/4885CA2 3040/4885CA3 4354/4885 |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | CA12 4718/4885CA2 4682/4885CA3 4794/4885 |
| US-20070161647-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS | KCNQ3, KCNK3, KCNK2 | CA12 2120/4885CA2 352/4885CA3 2006/4885 |
| US-20120253032-A1 | NOVEL CATIONIC LIPIDS WITH SHORT LIPID CHAINS FOR OLIGONUCLEOTIDE DELIVERY | NPC1L1, LDLR, NPC1 | CA12 3998/4885CA2 4168/4885CA3 4207/4885 |
| US-11679120-B2 | Circular RNA compositions and methods | RTCB, HNRNPA1, HNRNPAB | CA12 3727/4885CA2 4784/4885CA3 4577/4885 |
| US-11766449-B2 | Circular RNA compositions and methods | RTCB, RNGTT, HNRNPAB | CA12 4043/4885CA2 4833/4885CA3 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.